The psychedelic medicine renaissance: how could the route to market play out?

psychedelic_mushrooms_large

Psychedelics will soon be treating a mental health patient near you.

The quality and breadth of clinical data that has already emerged, coupled with ever-increasing regulatory and political acceptance - along with enormous need in the mental health space - mean that it is now only a matter of time before these compounds start to be authorized in multiple markets and conditions.

The idea that this might be happening would have seemed absurd only a few years ago, particularly when you consider that, for the most part, these compounds have been illegal and off limits to researchers for the past 50 years.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical